---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-005537"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:21:57.882436+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals receives FDA approval for DESMODA oral solution for central diabetes insipidus

## Summary
- FDA approved DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus in all ages; first approved oral liquid formulation.
- Commercial launch expected March 9; product available exclusively through Anovo specialty pharmacy.
- Eton estimates >13,000 U.S. patients; potential peak sales of $30-$50M annually.
- Patent protection through 2044; product leverages existing pediatric endocrinology rare disease sales team.
- Key safety warning: risk of hyponatremia; fluid restriction recommended; contraindicated in moderate to severe renal impairment.

## SEC filing metadata
- accession: 0001437749-26-005537
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/0001437749-26-005537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/eton20260223_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-005537
- JSON: https://secwatch.observer/filing/0001437749-26-005537.json
- Plain text: https://secwatch.observer/filing/0001437749-26-005537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.